Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture

Mickael Hiligsmann*, Setareh A. Williams, Lorraine A. Fitzpatrick, Stuart S. Silverman, Richard Weiss, Jean-Yves Reginster

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)184-196
Number of pages13
JournalSeminars in Arthritis and Rheumatism
Volume49
Issue number2
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Abaloparatide
  • Economic evaluation
  • Osteoporosis
  • Teriparatide
  • QUALITY-OF-LIFE
  • BONE-MINERAL DENSITY
  • POSTMENOPAUSAL WOMEN
  • VERTEBRAL FRACTURES
  • EXCESS MORTALITY
  • HIP FRACTURE
  • OSTEOPOROSIS TREATMENT
  • ORAL BISPHOSPHONATES
  • ECONOMIC-EVALUATION
  • HEALTH

Cite this